188 related articles for article (PubMed ID: 27438149)
1. Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.
Chang N; Lee HW; Lim JE; Jeong DE; Song HJ; Kim S; Nam DH; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Oncotarget; 2016 Aug; 7(32):51626-51639. PubMed ID: 27438149
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.
Hahn NM; Knudsen BS; Daneshmand S; Koch MO; Bihrle R; Foster RS; Gardner TA; Cheng L; Liu Z; Breen T; Fleming MT; Lance R; Corless CL; Alva AS; Shen SS; Huang F; Gertych A; Gallick GE; Mallick J; Ryan C; Galsky MD; Lerner SP; Posadas EM; Sonpavde G
Urol Oncol; 2016 Jan; 34(1):4.e11-7. PubMed ID: 26362343
[TBL] [Abstract][Full Text] [Related]
3. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
4. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Bianco R; Shin I; Ritter CA; Yakes FM; Basso A; Rosen N; Tsurutani J; Dennis PA; Mills GB; Arteaga CL
Oncogene; 2003 May; 22(18):2812-22. PubMed ID: 12743604
[TBL] [Abstract][Full Text] [Related]
5. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.
Koksal IT; Yasar D; Dirice E; Usta MF; Karauzum S; Luleci G; Baykara M; Sanlioglu S
Urol Int; 2005; 75(2):102-6. PubMed ID: 16123561
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of p53 and Pten promotes invasive bladder cancer.
Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C
Genes Dev; 2009 Mar; 23(6):675-80. PubMed ID: 19261747
[TBL] [Abstract][Full Text] [Related]
9. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Rebouissou S; Bernard-Pierrot I; de Reyniès A; Lepage ML; Krucker C; Chapeaublanc E; Hérault A; Kamoun A; Caillault A; Letouzé E; Elarouci N; Neuzillet Y; Denoux Y; Molinié V; Vordos D; Laplanche A; Maillé P; Soyeux P; Ofualuka K; Reyal F; Biton A; Sibony M; Paoletti X; Southgate J; Benhamou S; Lebret T; Allory Y; Radvanyi F
Sci Transl Med; 2014 Jul; 6(244):244ra91. PubMed ID: 25009231
[TBL] [Abstract][Full Text] [Related]
10. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.
Kiselyov A; Bunimovich-Mendrazitsky S; Startsev V
Int J Cancer; 2016 Jun; 138(11):2562-9. PubMed ID: 26547270
[TBL] [Abstract][Full Text] [Related]
11. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
[TBL] [Abstract][Full Text] [Related]
13. [Overexpression of PTEN gene inhibits proliferation of bladder transitional carcinoma cell line EJ].
Qiao BM; Sun G; Tang Y; Chang JW; Wang WC; Ma TX
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):262-5. PubMed ID: 17760251
[TBL] [Abstract][Full Text] [Related]
14. A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.
Fantini D; Glaser AP; Rimar KJ; Wang Y; Schipma M; Varghese N; Rademaker A; Behdad A; Yellapa A; Yu Y; Sze CC; Wang L; Zhao Z; Crawford SE; Hu D; Licht JD; Collings CK; Bartom E; Theodorescu D; Shilatifard A; Meeks JJ
Oncogene; 2018 Apr; 37(14):1911-1925. PubMed ID: 29367767
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
[TBL] [Abstract][Full Text] [Related]
16. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
17. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
[TBL] [Abstract][Full Text] [Related]
19. PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer?
Ashrafizadeh M; Zarrabi A; Samarghandian S; Najafi M
Eur J Pharmacol; 2020 Aug; 881():173226. PubMed ID: 32485246
[TBL] [Abstract][Full Text] [Related]
20. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
